Morphosys sees revenue boost as FDA approves psoriasis drug

DUESSELDORF/FRANKFURT (Reuters) - German biotech group Morphosys expects to receive royalties for its psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Authors: Galluzzo M, D'Adamio S, Campione E, Bianchi L, Talamonti M Abstract INTRODUCTION: Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of Th-17-derived pro-inflammatory cytokines, especially IL-17 and IL-22. Areas covered: In the following article, the mechanism of action and mainly the efficacy and safety profile of guselkumab available from results of trials will be discussed. We summarized these data after a literature review includi...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Michael P. Sch ön, Luise Erpenbeck
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study assesses the reliability of the PGA, measured by means of 0-100 mm visual analog scale (VAS), and the additional use of separate VAS scales for musculoskeletal (PhysMSK) and dermatologic (PhysSk) manifestations in patients with psoriatic arthritis (PsA). METHODS: Sixteen centers from 8 countries enrolled 319 consecutive patients with PsA. PGA, PhysMSK, and PhysSk evaluation forms were administered at enrollment (W0) and after 1 week (W1). Detailed clinical data regarding musculoskeletal (MSK) manifestations, as well as dermatological assessment, were recorded. RESULTS: Comparison of W0 and W1 scores sh...
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Condition:   Psoriasis Intervention:   Drug: Mirikizumab Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Choy M Abstract Burosumab-twza (Crysvita) for a rare inherited form of rickets; ibalizumab-uiyk (Trogarzo) for human immunodeficiency virus type 1 infection; and tildrakizumab-asmn (Ilumya) for adults with moderate-to-severe plaque psoriasis. PMID: 29896030 [PubMed]
Source: P and T - Category: Drugs & Pharmacology Tags: P T Source Type: research
In this report, we describe a case of widely spread unilateral ILVEN that clinically and histologically mimicked psoriasis vulgaris and could be diagnosed by immunohistochemical staining focused on the IL-36γ/IL-17A axis.Case Rep Dermatol 2018;10:170 –175
Source: Case Reports in Dermatology - Category: Dermatology Source Type: research
CONCLUSIONS: TSC results in considerable direct out-of-pocket medical costs and impairment to work productivity especially for adults. Future studies should include comparator group and examine direct cost burden in the US using electronic medical records and insurance databases. PMID: 29890870 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Biotechnology | Germany Health | Health | Psoriasis